Registration - In-house Corporation

Boehringer Ingelheim Canada Ltd. / Mark Lewis, President and CEO

Registration Information

In-house Corporation name: Boehringer Ingelheim Canada Ltd.
Responsible Officer Name: Mark Lewis, President and CEO
Responsible Officer Change History
Initial registration start date: 2022-05-30
Registration status: Active
Registration Number: 955680-371995

Associated Communications

Total Number of Communication Reports: 27

Monthly communication reports in the last 6 months: 3

Version 5 of 7 (2024-04-02 to 2024-09-26)

Registration versions:

Version 5 of 7 (2024-04-02 to 2024-09-26)

Lobbying Information

Subject Matter Details

Details Regarding the Identified Subject Matter
Subject matters	Details	Categories
Health	Arranging meetings to brief government officials on the business of Boehringer Ingelheim Canada Ltd.	Policies or Program
Health	Pharmaceutical pricing policy arising from the jurisdiction of the patented medicine prices review board (PMPRB).	Policies or Program

Communication Techniques

Written communication
Oral communication

Government Institutions

Agriculture and Agri-Food Canada (AAFC)
Finance Canada (FIN)
Global Affairs Canada (GAC)
Health Canada (HC)
House of Commons
Indigenous Services Canada (ISC)
Innovation, Science and Economic Development Canada (ISED)
Patented Medicine Prices Review Board (PMPRB)
Prime Minister's Office (PMO)

In-house Corporation Details

Description of activities

One of the world's leading research-driven pharmaceutical companies.

Responsible officer name and position during the period of this registration

Mark Lewis, President and CEO

Government funding

No government funding was received during the last completed financial year.

In-house Corporation Contact Information

Address:
5180 South Service Road
Burlington, ON L7L 5H4
Canada

Telephone number: 604-644-3171

Parent Company Information

Boehringer Ingelheim Canada Ltd. is not a subsidiary of any other parent companies.

Subsidiary Beneficiary Information

Boehringer Ingelheim Canada Ltd. does not have any subsidiaries that could have a direct interest in the outcome of the undertaking

Lobbyists Details

Senior Officers whose lobbying activities represent less than 20% of their Duties

Mark Lewis, President and CEO | No public offices held

Senior Officers and Employees whose lobbying activities represent 20% or more of their Duties

Mehmood Alibhai, Director of Patient Access & Healthcare Policy | No public offices held
Annie Beauchemin, Head, Market Access | No public offices held
Eve Blanchet, Regional Manager/ QUE, Patient Access and Health Policy | No public offices held
Gerald McCarron, Manager, External & Healthcare Affairs | No public offices held
Andrew Ransom, Manager, Patient Access | No public offices held

Boehringer Ingelheim Canada Ltd.

The following names have been used on or after July 2, 2008

The following names have been used on or after July 2, 2008
Name	From	To
Boehringer Ingelheim Canada Ltd.	2022-05-30	current

Boehringer Ingelheim Canada Ltd.

Responsible Officer History
Responsible Officer Name	From (YYYY-MM-DD)	To (YYYY-MM-DD)
Mark Lewis	2023-08-15	Current
Ruta Stauskas	2023-06-01	2023-08-15
Andrea Sambati	2022-05-30	2023-06-01

Date Modified:: 2024-12-05

Search and menus

Language selection

Registration - In-house Corporation

Boehringer Ingelheim Canada Ltd. / Mark Lewis, President and CEO

Registration Information

Associated Communications

Version 5 of 7 (2024-04-02 to 2024-09-26)

Version 5 of 7 (2024-04-02 to 2024-09-26)

Subject Matter Details

Communication Techniques

Government Institutions

Description of activities

Responsible officer name and position during the period of this registration

Government funding

In-house Corporation Contact Information

Parent Company Information

Subsidiary Beneficiary Information

Senior Officers whose lobbying activities represent less than 20% of their Duties

Senior Officers and Employees whose lobbying activities represent 20% or more of their Duties